SN7
SHORT NOTE
5M
Classify the immunosuppressant drugs. Describe the calcineurin inhibitors and the complications of immunosuppression.
Classification of Immunosuppressants
| Class | Drugs | Mechanism |
|---|---|---|
| Calcineurin inhibitors | Ciclosporin, tacrolimus | Bind cyclophilin and FKBP respectively, and the complex inhibits calcineurin, so NFAT cannot activate IL-2 transcription — T-cell activation fails. The backbone of transplant immunosuppression |
| MTOR inhibitors | Sirolimus (rapamycin), everolimus | Block the mTOR pathway and so IL-2-driven T-cell proliferation; not nephrotoxic, so useful where renal function is a concern |
| Antiproliferative | Azathioprine, mycophenolate mofetil | Azathioprine is converted to 6-mercaptopurine and inhibits purine synthesis; mycophenolate inhibits inosine monophosphate dehydrogenase, on which lymphocytes depend selectively for purine synthesis |
| Corticosteroids | Prednisolone, methylprednisolone | Broad suppression of cytokine transcription; used for induction, maintenance and rejection episodes |
| Cytotoxic | Cyclophosphamide, methotrexate | Vasculitis, lupus nephritis, and severe autoimmune disease |
| Biologicals | Basiliximab (anti-IL-2 receptor), antithymocyte globulin, rituximab (anti-CD20), belatacept, anti-TNF agents, tocilizumab | Induction therapy, steroid-resistant rejection, and autoimmune disease |
| JAK inhibitors | Tofacitinib, baricitinib | Autoimmune disease |
Calcineurin Inhibitors in Detail
- Narrow therapeutic index requiring level monitoring — too little causes rejection, too much causes nephrotoxicity, and the window between them is small
- Nephrotoxicity is the central problem — both acute (reversible afferent arteriolar constriction) and chronic (irreversible interstitial fibrosis); paradoxically, the drug that saves a transplanted kidney also damages it
- Ciclosporin — additionally causes gum hypertrophy, hirsutism, hypertension, hyperlipidaemia, hyperkalaemia, hypomagnesaemia and tremor
- Tacrolimus — more potent, and now generally preferred; causes less hirsutism and gum change but more diabetes (post-transplant diabetes mellitus), neurotoxicity and alopecia
- Both are metabolised by CYP3A4, so interactions are numerous and clinically serious — levels are raised by azoles, macrolides, diltiazem, verapamil and grapefruit juice, and lowered by rifampicin, phenytoin, carbamazepine and ST JOHN wort
CLINICAL PEARL
An interaction that changes a calcineurin inhibitor level can cost the patient the graft. Add rifampicin and the level collapses, and rejection follows; add an azole antifungal and the level soars, and the kidney is damaged. This is why every new prescription for a transplant patient — including antibiotics, antifungals and herbal preparations — must be checked against the immunosuppressant, and why patients are told never to take anything without asking.
Complications of Immunosuppression
- Infection — the dominant risk: bacterial, and opportunistic organisms including cytomegalovirus, Pneumocystis, fungi, tuberculosis, and reactivation of hepatitis B and herpes viruses. Prophylaxis with co-trimoxazole and valganciclovir is routine
- Malignancy — particularly skin cancer and post-transplant lymphoproliferative disease (EBV-driven); the risk relates to the total burden and duration of immunosuppression
- Drug-specific toxicity — nephrotoxicity, diabetes, hypertension, dyslipidaemia, bone loss, marrow suppression
- Mycophenolate is teratogenic, causing characteristic malformations; pregnancy must be excluded and contraception used, and it is switched to azathioprine before a planned pregnancy
- Live vaccines are contraindicated; inactivated vaccines should be given before transplantation wherever possible
Applied Aspects
- Check every new drug against the immunosuppressant before prescribing for a transplant patient, and warn them explicitly about over-the-counter and herbal preparations
- Screen for tuberculosis and hepatitis B before starting any prolonged immunosuppression — essential in India, where the background prevalence makes reactivation a real and frequently fatal event
- Never allow a transplant patient to run out of medication; a few missed days can cause irreversible rejection, and cost or supply interruption is a genuine cause of graft loss in India
- Take fever seriously and investigate broadly; the usual inflammatory signs are blunted and the differential includes organisms that would not trouble a normal host
- Advise sun protection and annual skin examination, given the substantially raised risk of skin malignancy
- Check TPMT before azathioprine and never combine it at full dose with allopurinol, which blocks its inactivation by xanthine oxidase and causes profound marrow suppression
All questions in Blood, Haematinics & Anticancer Drugs
- Q1Define haematinics. Describe iron metabolism, iron preparations, vitamin B12 and folic acid with their uses. ★
- Q2Classify the haemostatic drugs. Describe vitamin K, tranexamic acid and the treatment of haemophilia. ★
- Q3Describe the general principles of cancer chemotherapy including the cell cycle, log kill hypothesis, combination therapy, resistance and toxicity. ★
- Q4Classify the cytotoxic anticancer drugs. Describe the alkylating agents, antimetabolites and natural products with their distinctive toxicities. ★
- Q5Describe the hormonal agents, targeted therapy and immunotherapy used in cancer. ★
- SN1Describe oral and parenteral iron therapy with the monitoring of response and the management of iron overload. ★
- SN2Describe vitamin B12 and folic acid with their deficiency states and treatment. ★
- SN3Describe the haematopoietic growth factors with their uses and adverse effects. ★
- SN4Describe methotrexate with its mechanism, uses, adverse effects and interactions. ★
- SN5Describe cisplatin and the platinum compounds with their uses and toxicity. ★
- SN6Describe the adverse effects of cancer chemotherapy and their prevention and management. ★
- SN7Classify the immunosuppressant drugs. Describe the calcineurin inhibitors and the complications of immunosuppression.